SalaryGuide
AboutPricingFor Employers

Marketing jobs

24 marketing jobs

Astellas Pharma logo
2 months ago

Global Brand Strategy & Marketing Content Specialist

Astellas Pharma

Addlestone, Hounslow, UK (Hybrid)Full time
Wild at Heart logo
2 months ago

Social Strategy & Content Manager (Maternity Cover)

Wild at Heart

London, UK (On-site)Full time
Epsilon logo
2 months ago

Strategic Client Services Manager

Epsilon

London, UK (Hybrid)Full time
Brave Bison Ltd logo
3 months ago

Content Strategy Consultant

Brave Bison Ltd

Manchester, UK (Hybrid)Full time
Previous
12
Next

All Content Strategy roles in the UK

Get alerts for this search

All Content Strategy roles in the UK

Get alerts for this search

24 jobs
Astellas Pharma logo

Global Brand Strategy & Marketing Content Specialist

Astellas Pharma

Addlestone, Hounslow, UK (Hybrid)

In-houseFull-timeMid level
2 months ago
Wild at Heart logo

Social Strategy & Content Manager (Maternity Cover)

Wild at Heart

London, UK (On-site)

In-houseFull-timeMid level4+ years exp.
2 months ago
Epsilon logo

Strategic Client Services Manager

Epsilon

London, UK (Hybrid)

In-houseFull-timeMid level2+ years exp.
2 months ago
Brave Bison Ltd logo

Content Strategy Consultant

Brave Bison Ltd

Manchester, UK (Hybrid)

AgencyFull-timeMid level
3 months ago
Previous12
Astellas Pharma logo
Astellas Pharma

Global Brand Strategy & Marketing Content Specialist

Addlestone, Hounslow, UK (Hybrid)

Salary Not AvailableMid LevelFull time

Posted 2 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own cross‑functional content operations for a regulated life sciences portfolio, coordinating global assets, reviews, and digital tooling to ensure scalable, compliant materials and market access alignment.

  • Own end-to-end content workflows and digital‑innovation enablement to improve engagement across affiliates and channels.
  • Collaborate with regulatory and review stakeholders to streamline approvals and maintain consistent global asset libraries and metadata quality.

Job Description

Responsibilities

  • Supporting global brand and scientific marketing teams by planning, creating, and approving high-impact content.
  • Delivering light medical writing by developing and adapting brand assets for global use.
  • Owning end-to-end content project management by coordinating internal creative and production workflows.
  • Leveraging knowledge of digital innovation by applying content and marketing technologies to enhance engagement.
  • Serving as a Veeva PromoMats SME by managing workflows and coordinating with internal and external partners.
  • Collaborating with ABC/MLR reviewers by ensuring seamless review and approval of marketing materials.
  • Building and maintaining scalable content ecosystems by managing portals, libraries, modular assets, and metadata accuracy.
  • Driving global content effectiveness by enabling affiliate alignment, sharing best practices, and establishing KPI frameworks for data-driven decision-making.
  • Identify and support market access activities to ensure availability of Astellas brands in line with pricing and reimbursement strategies.
  • Support positioning of brands within treatment guidelines and diagnostic protocols.

Requirements

  • Bachelor’s degree or equivalent
  • Solid experience in content creation, copywriting, content localization, and digital/omnichannel engagement within the pharmaceutical, life sciences, or other highly regulated industries
  • Medical copywriting experience gained within an agency or life sciences company
  • Strong experience working with data, analytics, and insights, with the ability to translate data into meaningful information that supports decision-making
  • Proven track record of delivering complex, multi-stakeholder projects and initiatives
  • Experience working within pharma brand teams and content creation, and/or brand marketing, including digital strategy, digital marketing, and multi-channel content delivery
  • Up-to-date knowledge of innovations in content strategy, including modular content approaches and evolving content operations
  • Strong communication and presentation skills, with the ability to influence and engage senior leaders and key stakeholders

Preferred

  • Science degree or equivalent.
  • Experience in omnichannel content within pharmaceutical, life sciences, FMCG, or other content-driven industries, or within an advertising/marketing agency
  • Familiarity with Legal, Medical, and Regulatory (LMR) review processes and local compliance requirements
  • Sales or field experience engaging with HCPs, payers, and patients
  • Exposure to oncology or other specialist therapeutic areas
  • Forward-thinking mindset with a strong interest in digital transformation and innovation in content and marketing platforms

Benefits

  • Global collaboration: Become part of a connected global business of like-minded life science leaders, all dedicated to improving patients' lives worldwide.
  • Real-world patient impact: Contribute to transformative therapies that reach patients around the world, knowing your work makes a difference every day.
  • Relentless Innovation: Join a company at the forefront of scientific breakthroughs, where you'll have the opportunity to shape the future of healthcare.
  • A Culture of Growth: Chart your own course within a supportive environment that values your contributions, champions your development, and empowers you to pursue your passions.
  • We are an equal opportunity employer, and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law.
  • Beware of recruitment scams impersonating Astellas recruiters or representatives. Authentic communication will only originate from an official Astellas LinkedIn profile or a verified company email address. If you encounter a fake profile or anything suspicious, report it promptly to LinkedIn's support team through LinkedIn Help.
Astellas Pharma logo

Astellas Pharma

3.3 Glassdoor

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Founded in 2005
Chuo-ku, Tokyo, JPN
12K employees (737 in marketing)
www.astellas.com
48% recommend to a friend
51% CEO approval

Traffic Signals

Monthly Visitors
207.7K
Traffic Source Mix
Search
53.5%
Direct
36.3%
Referral
8.3%
Social
1.1%
Paid
0.7%

Headcount Trend

Current headcount: ~12K

Marketing Team

Marketing Team Size
672 (6% of company)

Funding

Last Raise
Grant, 6 years ago

Funding History

  • Jul 2020
    Grant

Recent News

アステラス製薬(東証:4503)が5.9%上昇した理由 オンコロジーの売上とコストコントロールで業績予想を上方修正
Nov 4, 2025 • simplywall.st
アステラス製薬、Azureへの移行により世界6か所のデータセンターを閉鎖
Oct 28, 2025 • Microsoft
アステラス製薬(東証:4503)のブルケースは、主要なフェーズ3オンコロジー・ミルストンに続いて変化する可能性がある-その理由を学ぶ
Oct 27, 2025 • simplywall.st
アステラス製薬(東証:4503)の膵臓癌におけるゾルベツキシマブ第2相試験の後退に対する投資家の反応について
Oct 17, 2025 • simplywall.st
アステラス製薬(4503)はカナダでVYLOYの償還を拡大すべきか?
Oct 10, 2025 • simplywall.st
研究開発 | アステラス製薬
Oct 7, 2025 • Astellas
移植免疫学 | アステラス製薬
Oct 7, 2025 • Astellas
創薬におけるオープンイノベーション | アステラス製薬
Oct 7, 2025 • Astellas
Primary Focuses | アステラス製薬
Oct 7, 2025 • Astellas
アステラス・ グローバルヘルス財団
Oct 7, 2025 • Astellas
個人投資家の皆さま | アステラス製薬
Oct 7, 2025 • Astellas
United States Cancer Therapeutics Market to Hit $491.6 Billion by 2032, Driven by Precision and Immunotherapy Advances
Sep 29, 2025 • EIN Presswire
Astellas Announces Top Management Personnel Change
Sep 29, 2025 • Morningstar.com
Astellas Announces Top Management Personnel Change
Sep 29, 2025 • PR Newswire
Astellas Pharma Chief Digital & Transformation Officer to leave on September 30
Sep 29, 2025 • thefly.com
Astellas Announces Top Management Personnel Change
Sep 29, 2025 • MarketScreener
Astellas Announces Top Management Personnel Change
Sep 29, 2025 • BioSpace
IgA Nephropathy Treatment Market to Hit $3.24 Billion by 2033, Fueled by ACE Inhibitors & Novel Therapies
Sep 26, 2025 • EIN Presswire
アステラス製薬(東証:4503)にとって日本初の筋萎縮症治療薬がゲームチェンジャーとなる可能性
Sep 24, 2025 • simplywall.st
Conditional approval for Izervay in Japan
Sep 19, 2025 • Pharma Letter
Astellas Pharma Wins Conditional Japan Approval for First Treatment to Slow Vision Loss From Geographic Atrophy
Sep 19, 2025 • MarketScreener
Shionogi strengthens its position by acquiring Torii
Sep 17, 2025 • MarketScreener
Topical Drugs Market Size to Reach USD 311.88 Billion by 2032, Fueled by Rising Skin Disorder Prevalence and Innovative Drug Delivery Systems
Sep 15, 2025 • SNS Insider pvt ltd
Mid-West Sustainability Network Launches Sustainability Week 2025
Sep 12, 2025 • Irish Tech News
Lilly loses bid to nix $184m Medicaid fraud penalty
Sep 12, 2025 • pharmaphorum
FibroGen pays SEC $1.2M over allegations former exec 'reverse engineered' roxadustat data
Sep 11, 2025 • FierceBiotech
CHARM Therapeutics Appoints Dr Erkut Bahceci as Chief Medical Officer
Sep 7, 2025 • Morningstar.com
Astellas attacks menopause stigma with new workplace inclusivity program
Sep 5, 2025 • FiercePharma
Poll paints picture of menopause discrimination at work
Sep 5, 2025 • pharmaphorum
Astellas Pharma just downgraded at Bernstein, here's why
Sep 2, 2025 • thefly.com
Pfizer lays off 100 workers at former Seagen HQ in Seattle area
Aug 26, 2025 • FiercePharma
Stomach Cancer Market is Forecasted to Reach a Value of US $6.28 Billion by 2029
Aug 22, 2025 • EIN Presswire
NICE backs enfortumab vedotin with Keytruda for metastatic urothelial cancer
Aug 21, 2025 • Pharma Letter
NICE backs bladder cancer duo that can double survival
Aug 21, 2025 • pharmaphorum
By 2030, the global liver disease treatment market is forecasted to achieve $36.45 billion, expanding at a CAGR of 5.7%.
Aug 20, 2025 • EIN Presswire
12.6% CAGR for Cancer Drugs Market to Reach US$516.15 billion by 2031, Due to Surging Investments in Oncology Research | The Insight Partners
Aug 19, 2025 • PR Newswire
12.6% CAGR for Cancer Drugs Market to Reach US$516.15 billion by 2031, Due to Surging Investments in Oncology Research | The Insight Partners
Aug 19, 2025 • PR Newswire UK
FLT3 inhibitors for acute myeloid leukemia market
Aug 15, 2025 • PharmiWeb
Assessment of the $118+ Billion Vaccines Market, 2030, Featuring Strategic Analysis of 30 Industry Players
Aug 14, 2025 • Research and Markets
Padcev/Keytruda extends survival in early bladder cancer
Aug 13, 2025 • pharmaphorum
CIO50 Australia Team of the Year 2025 finalists unveiled
Aug 13, 2025 • How I turned our IT dashboard into a strategic control tower | CIO
Antibody Drug Conjugate (ADC) Market Report 2025: Industry Set to Double by 2030 Driven by Next-Gen Oncology Innovations, Reaching $16 Billion
Aug 13, 2025 • Research and Markets
Pfizer, Astellas Pharma See Positive Trial Results From Bladder-Cancer Treatment
Aug 12, 2025 • Morningstar.com
Pfizer, Astellas Say Padcev-Keytruda Combo Therapy Shows Improved Survival in Bladder Cancer Patients
Aug 12, 2025 • MarketScreener
Open-Angle Glaucoma Market to Hit USD 9.39 Billion by 2032, Driven by CAGR 10.4% From 2025 to 2032
Aug 8, 2025 • EIN Presswire
Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight
Aug 6, 2025 • PR Newswire UK
10 oncology deals in 2025 spotlight where industry leaders are betting big
Aug 5, 2025 • Labiotech.eu
Transcript : Astellas Pharma Inc., Q1 2026 Earnings Call, Jul 30, 2025
Aug 4, 2025 • MarketScreener
アステラス製薬、戦略的理由により全身投与型腫瘍溶解性ウイルスの開発中止
Jul 31, 2025 • 日経バイオテクONLINE
Japan’s Astellas Pharma hits 8-mth high on upbeat Q1 earnings
Jul 30, 2025 • Investing.com
Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting
Jul 29, 2025 • PR Newswire
Big pharma aggregate revenue up 7.9% in 2024
Jul 29, 2025 • Pharma Letter
Candidemia Market Analysis and Forecast Report 2025-2035 Featuring Pfizer, Cidara Therapeutics, Scynexis, Merck, Basilea Pharmaceutica, Lupin Pharmaceuticals, Astellas Pharma - ResearchAndMarkets.com
Jul 29, 2025 • Business Wire
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight
Jul 29, 2025 • PR Newswire UK
Biopharma's R&D Surge: Propelling Oncology & Cancer Drugs Market with a Projected 7.5% CAGR
Jul 29, 2025 • EIN Presswire
Bio Pharmaceuticals Market: A Comprehensive Analysis of Growth, Trends, and Opportunities
Jul 25, 2025 • PharmiWeb
Spinal Muscular Atrophy Treatment Market to Hit USD 16.28 Billion by 2032, Driven by Early Diagnosis and Advanced Therapies - SNS Insider
Jul 25, 2025 • SNS Insider pvt ltd
Postherpetic Neuralgia PHN Market To Reach $0.99 Billion By 2029 With A Growth Rate Of 6.6%
Jul 24, 2025 • EIN Presswire
China Exit Ban on Wells Fargo Executive Stokes Foreign Business Anxiety
Jul 21, 2025 • NYT > Business
Candidemia Market Research Report 2025-2035 | Rising Incidence and Drug Innovation Fuel Growth, Antifungal Therapies Drive Expansion
Jul 21, 2025 • Research and Markets
Japan national sentenced to 3-1/2 years in prison in China has no plan to appeal, Kyodo says
Jul 19, 2025 • Reuters
Japan national sentenced to 3-1/2 years in prison in China has no plan to appeal, Kyodo says
Jul 19, 2025 • MarketScreener
Japan national sentenced to 3-1/2 years in prison in China has no plan to appeal, Kyodo says
Jul 19, 2025 • Reuters
Astellas links up with KISED to support Korean biotech start-ups
Jul 18, 2025 • Pharma Letter
Factbox-Foreign firms’ executives entangled in Chinese probes
Jul 18, 2025 • Investing.com
Astellas Pharma enters MOU with KISED for pact with Global Companies Program
Jul 17, 2025 • thefly.com
Foreign firms' executives entangled in Chinese probes
Jul 17, 2025 • MarketScreener
中国、アステラス製薬社員に拘禁刑3年6カ月 「スパイ容疑」巡り
Jul 16, 2025 • 朝日新聞
Chinese Court Jails Japanese Executive in Spying Case, Report Says
Jul 16, 2025 • Livemint.com
Vernal Keratoconjunctivitis Market Research Report 2025-2035 | Rising Pediatric Allergies and Enhanced Awareness Fuel Growth
Jun 24, 2025 • Research and Markets
Leading Driver In The Oral Hypoglycemic Agents Market 2025: Rising Prevalence Of Type 2 Diabetes Driving Growth
Jun 20, 2025 • EIN Presswire
Global Metastatic Lung Adenocarcinoma Treatment Market To Reach $6.64 Billion By 2029 With A Growth Rate Of 9.9%
Jun 20, 2025 • EIN Presswire
AI in Drug Discovery and Development Market Size, Trends, Growth Forecast 2025–2033 | DataM Intelligence
Jun 19, 2025 • EIN Presswire
10.0% CAGR Fuels Top 10 Cancer Drugs Market to $198.8 Billion by 2032
Jun 19, 2025 • EIN Presswire
Atopic Dermatitis Market to Reach $22.6 Billion by 2031, Driven by Biologics and Technological Advancements
Jun 18, 2025 • EIN Presswire
Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
Jun 17, 2025 • DelveInsight Business Research LLP
The Cephalosporin Drugs Market Analysis 2025: Insights for Long-Term Investment & Planning
Jun 16, 2025 • EIN Presswire
Atypical Mycobacteriosis Treatment Market Report 2025 – Insights for Companies Seeking Growth & Advantage
Jun 16, 2025 • EIN Presswire
Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
Jun 13, 2025 • Morningstar.com
Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
Jun 13, 2025 • BioSpace
Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
Jun 13, 2025 • PR Newswire
Key Market Driver In Cyclosporine Drugs Market Industry 2025: Surge In Organ Transplantation Driving The Growth Market
Jun 13, 2025 • EIN Presswire
Global Chemotherapy-Induced Neutropenia Treatment Market To Reach $0.76 Billion By 2029 With A Growth Rate Of 5.3%
Jun 13, 2025 • EIN Presswire
Astellas offers lab space to startups to help Japanese biotechs 'go global'
Jun 13, 2025 • FierceBiotech
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
Jun 10, 2025 • BioSpace
Geographic Atrophy Market at a Turning Point: From Slowing Progression to Restoring Vision | Competitive Intelligence
Jun 9, 2025 • EIN Presswire
Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast Report 2025 | Profiling Key Innovators in CIPN Therapeutics
Jun 4, 2025 • Research and Markets
Overactive Bladder Treatment Market to Reach USD 5.45 Billion by 2032, Driven by Aging Population, Drug Innovation, and Rising Awareness – SNS Insider
Jun 4, 2025 • SNS Insider pvt ltd
Astellas selects Veeva Vault CRM as global commercial platform
Jun 4, 2025 • Pharmafile
Global Facial Erythema Treatment Market Anticipates 5% CAGR Growth with Emerging Solutions by 2030
Jun 2, 2025 • PharmiWeb
Global Vitreoretinal Disorder Market: Key Drivers, Trends, Growth Opportunities & Forecast 2025–2034 – Insights
May 30, 2025 • EIN Presswire
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
May 30, 2025 • MarketScreener
Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B
May 30, 2025 • BioWorld Financial Watch
Astellas inks ADC deal with Evopoint Biosciences for XNW27011
May 30, 2025 • Pharma Letter
アステラス製薬(4503 JP):2025年度は好調な業績、コスト最適化により2026年度は売上高横ばいながら利益が増加
Apr 28, 2025 • Smartkarma
Regenerative Medicine Market to Surpass USD 22,051.2 Mill...
Apr 10, 2025 • PharmiWeb
Bispecific Antibodies Market Forecasted to Reach USD 30 Billion By 2035, at an Impressive 10.47% CAGR
Apr 9, 2025 • EIN Presswire
Global Lung Disease Therapeutics Market Set to Reach USD...
Apr 9, 2025 • PharmiWeb
Age-related Macular Degeneration Market Report 2025-2030 - Asia-Pacific and EMEA Fuel Growth in AMD Market with Reforms and Expanding Access to Vision Care
Apr 8, 2025 • Research and Markets
Antibody Drug Conjugates Market Size | USD 21.27 Bn & CAG...
Apr 8, 2025 • PharmiWeb